Harlan Robins Sells 386,240 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Harlan Robins sold 386,240 shares of the business’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $22.01, for a total transaction of $8,501,142.40. Following the sale, the insider directly owned 1,019,658 shares in the company, valued at $22,442,672.58. This trade represents a 27.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Adaptive Biotechnologies Trading Down 3.2%

Shares of NASDAQ:ADPT traded down $0.68 during trading on Tuesday, hitting $20.82. 2,439,820 shares of the company were exchanged, compared to its average volume of 2,277,637. The stock has a market cap of $3.33 billion, a price-to-earnings ratio of -63.09 and a beta of 2.07. Adaptive Biotechnologies Corporation has a fifty-two week low of $9.96 and a fifty-two week high of $22.80. The firm has a fifty day moving average price of $16.24 and a two-hundred day moving average price of $15.90.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.03. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. The company had revenue of $70.87 million for the quarter, compared to analyst estimates of $61.03 million. During the same period in the previous year, the business earned ($0.20) EPS. Adaptive Biotechnologies’s revenue for the quarter was up 35.1% compared to the same quarter last year. As a group, research analysts predict that Adaptive Biotechnologies Corporation will post -0.47 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on ADPT shares. BTIG Research reissued a “buy” rating and issued a $22.00 price objective on shares of Adaptive Biotechnologies in a research note on Wednesday, June 17th. Guggenheim lifted their price target on Adaptive Biotechnologies from $21.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, June 29th. TD Cowen boosted their price target on Adaptive Biotechnologies from $19.00 to $21.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. Morgan Stanley dropped their price objective on Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 12th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Monday, April 20th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $20.50.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. 1492 Capital Management LLC bought a new position in shares of Adaptive Biotechnologies in the 4th quarter worth about $1,484,000. Jupiter Asset Management Ltd. grew its stake in Adaptive Biotechnologies by 33.8% during the fourth quarter. Jupiter Asset Management Ltd. now owns 362,811 shares of the company’s stock worth $5,892,000 after purchasing an additional 91,683 shares during the period. Rhenman & Partners Asset Management AB increased its holdings in Adaptive Biotechnologies by 22.2% in the fourth quarter. Rhenman & Partners Asset Management AB now owns 605,000 shares of the company’s stock worth $9,825,000 after purchasing an additional 110,000 shares in the last quarter. UBS Group AG lifted its stake in Adaptive Biotechnologies by 101.6% in the fourth quarter. UBS Group AG now owns 511,927 shares of the company’s stock valued at $8,314,000 after buying an additional 257,947 shares during the period. Finally, Westfield Capital Management Co. LP acquired a new stake in shares of Adaptive Biotechnologies during the 4th quarter worth approximately $65,942,000. 99.17% of the stock is currently owned by institutional investors and hedge funds.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.